- Home
- PDO vs AZTA Comparison
PDO vs AZTA Comparison
Compare PDO & AZTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PDO
- AZTA
- Stock Information
- Founded
- PDO 2020
- AZTA 1978
- Country
- PDO United States
- AZTA United States
- Employees
- PDO N/A
- AZTA N/A
- Industry
- PDO Trusts Except Educational Religious and Charitable
- AZTA Industrial Machinery/Components
- Sector
- PDO Finance
- AZTA Technology
- Exchange
- PDO Nasdaq
- AZTA Nasdaq
- Market Cap
- PDO 1.7B
- AZTA 1.8B
- IPO Year
- PDO N/A
- AZTA 1995
- Fundamental
- Price
- PDO $13.49
- AZTA $33.23
- Analyst Decision
- PDO
- AZTA Buy
- Analyst Count
- PDO 0
- AZTA 3
- Target Price
- PDO N/A
- AZTA $50.67
- AVG Volume (30 Days)
- PDO 520.0K
- AZTA 1.0M
- Earning Date
- PDO 01-01-0001
- AZTA 08-05-2025
- Dividend Yield
- PDO 11.80%
- AZTA N/A
- EPS Growth
- PDO N/A
- AZTA N/A
- EPS
- PDO N/A
- AZTA N/A
- Revenue
- PDO N/A
- AZTA $669,171,000.00
- Revenue This Year
- PDO N/A
- AZTA N/A
- Revenue Next Year
- PDO N/A
- AZTA $4.89
- P/E Ratio
- PDO N/A
- AZTA N/A
- Revenue Growth
- PDO N/A
- AZTA 8.56
- 52 Week Low
- PDO $10.65
- AZTA $23.91
- 52 Week High
- PDO $13.31
- AZTA $63.58
- Technical
- Relative Strength Index (RSI)
- PDO 55.46
- AZTA 70.26
- Support Level
- PDO $13.32
- AZTA $29.79
- Resistance Level
- PDO $13.38
- AZTA $31.42
- Average True Range (ATR)
- PDO 0.08
- AZTA 1.40
- MACD
- PDO 0.01
- AZTA 0.28
- Stochastic Oscillator
- PDO 91.67
- AZTA 95.02
About PDO PIMCO Dynamic Income Opportunities Fund of Beneficial Interest
PIMCO Dynamic Income Opportunities Fund is a closed-end management investment company. The fund's primary investment objective is to generate a level of income that is higher than that generated by high-quality, intermediate-term U.S. debt securities.
About AZTA Azenta Inc.
Azenta Inc is a provider of life sciences solutions, enabling impactful breakthroughs and therapies to market faster. It provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. The company has two reportable segments that are Life Sciences Products and Life Sciences Services. It generates a substantial part of its revenue from its Life Sciences Services segment.